The beneficial effect of metformin on β‐cell function in non‐obese Chinese subjects with newly diagnosed type 2 diabetes
Diabetes/Metabolism Research and Reviews2013Vol. 29(8), pp. 664–672
Citations Over TimeTop 14% of 2013 papers
Yan Bi, Guobang Tong, Haiyan Yang, Mengyin Cai, Juan Manuel Malacara, Jun Liang, Xin Bin, Haijun Miao, Zhaokang Peng, Dalong Zhu
Abstract
Metformin improved β-cell function in non-obese subjects with newly diagnosed T2DM, which was partly independent of the change in insulin sensitivity in these subjects. This study provides evidence-based data to support metformin use in non-obese patients with T2DM as the first-line agent, which can improve both insulin sensitivity and β-cell function.
Related Papers
- → Glipizide: A Second‐generation Sulfonylurea Hypoglycemic Agent; Pharmacology, Pharmacokinetics and Clinical Use(1985)51 cited
- → Comparative Efficacy of a Once-Daily Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Patients With NIDDM(1994)53 cited
- → Glipizide, a new oral antidiabetic agent (report of a controlled clinical study in Sweden)(1973)7 cited
- Efficacy of Controlled-Release Glipizide in Treatment of Type 2 Diabetes(2001)